Europe Molecular Diagnostics Market Is Expected To Witness Growth Based On Rising Geriatric Population And The Increasing Prevalence Of Neurological And Cardiovascular Disorders Till 2024

The europe molecular diagnostics market is expected to reach USD4.0 billion by 2024, according to a new report by Grand View Research, Inc. Growing geriatric population and the increasing prevalence of neurological and cardiovascular disorders is expected to drive the growth of molecular diagnostics. Moreover, increasing demand for more efficient healthcare delivery to facilitate early diagnostics is further expected to boost market growth.

Rising awareness levels among individuals pertaining to the availability of effective molecular diagnostic tests to determine the presence of genetic disorders is expected to increase the client base for this industry, consequently leading to early diagnosis of disorders in the population.

In addition, with the demand for high levels of accuracy and cost effectiveness of diagnostic procedures, the existent technologies are continually undergoing progressive changes to develop improved and efficient testing tools. Presence of a number of established healthcare facilities coupled with the technological advancements facilitating and expediting accurate disease diagnosis are expected to serve this market as significant drivers fueling growth.

Browse full research report on global europe molecular diagnostics market:

Further key findings from the study suggest:

  • The overall vertical was dominated by the reagents with their revenue generation estimated at over USD 930.0 million in 2015 owing to their higher usage including formamide, salts, and dextran sulphate or heparin employed in the drug development process to detect disease-related novel biomarkers
  • Introduction of reagents for technologically advanced instruments are anticipated to attribute towards an attractive growth of reagents segment over the forecast period
  • Central laboratories held the largest market share of around 60% in 2015 owing to the highly developed healthcare infrastructure and skilled healthcare professionals & staff associated with them.
  • Point of care is the fastest growing test location segment with an estimated CAGR of over 12.0% over the forecast period. Increasing demand for expedited diagnosis and rapid analysis has led to the growth of this section.
  • Infectious diseases dominated the market on the basis of application with the largest revenue contribution in 2015 owing to the large test volumes and extensive portfolio of commercialized products in this area.
  • HIV held the largest market share of around 14.0% in 2015 in the infectious disease segment. Government initiatives being undertaken in Italy and France to create higher awareness about infectious diseases, such as HIV/AIDS and Hepatitis B, are factors responsible for its high market share.
  • Polymerase chain reaction (PCR) technology dominated the vertical with overall market revenue of over USD 725.0 million, attributable to the increasing application of molecular diagnostics in the field of drug discovery & development and pharmacogenomics
  • DNA sequencing is estimated to emerge as a profitable market over the forecast period with a CAGR of around 15.0%. With the sweeping technological advancements in the field, DNA sequencing is presently one of the most cost-effective technologies used to decode the genetic cause underlying a range of diseases.
  • The next generation sequencing technology segment will witness the highest growth rate throughout the forecast period majorly owing to the increasing R&D initiatives for development of novel drugs.
  • Germany held the largest market share with maximum revenue generation in 2015, which is attributed primarily to its huge elderly population base. Growing geriatric population coupled with decreased immune levels would engender the widespread prevalence of chronic diseases conditions comprising cardiovascular, neurological, and diabetes
  • The molecular diagnostics sector in the UK is estimated to grow at a faster rate with a CAGR of over 11.0% throughout the forecast period. The presence of sophisticated healthcare infrastructure, higher disposable income, and the increasing R&D intensity are the key factors contributing towards the growth of this sector in the UK.
  • Some leading companies in the molecular diagnostics sector include Roche Diagnostics, Alere Inc., Cepheid, Hologic, Inc. (Gen Probe), Sysmex Corporation, Abbott Laboratories, Bayer AG, Siemens Healthcare GmbH, Becton, Dickinson and Company, Johnson & Johnson, bioMérieux SA, Dako, Novartis AG (Grifols), Danaher Corporation, Bio-Rad Laboratories, Inc., and Qiagen N.V.
  • The established players in this vertical are adopting strategies, such as mergers and acquisitions, new product development, expansion activities pertaining to R&D of novel diagnostic products, and strategic collaborations to widen their existent product portfolios

Browse more reports of this category by Grand View Research:

Grand View Research has segmented the Europe molecular diagnostics market on the basis of product, technology, applications, test location, and country:

Europe Molecular Diagnostics Product Outlook (Market Revenue in USD Million, 2013 – 2024)

  • Instruments
  • Reagents
  • Others

Europe Molecular Diagnostics Test Location Outlook (Market Revenue in USD Million, 2013 – 2024)

  • Point of care
  • Self-testing or OTC
  • Central laboratories

Europe Molecular Diagnostics Technology Outlook (Market Revenue in USD Million, 2013 – 2024)

  • PCR
  • In-situ hybridization
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Chips and microarrays
  • Mass spectrometry
  • Sequencing
  • Transcription-mediated amplification
  • Others

Europe Molecular Diagnostics PCR, by segments Outlook (Market Revenue in USD Million, 2013 – 2024)

  • Multiplex PCR
  • Others

Europe Molecular Diagnostics Application Outlook (Market Revenue in USD Million, 2013 – 2024)

  • Oncology
  • Pharmacogenomics
  • Infectious diseases
  •  Genetic testing
  • Neurological diseases
  • Cardiovascular diseases
  • Microbiology
  • Others

Europe Molecular Diagnostics Oncology, By Application Outlook (Market Revenue in USD Million, 2013 – 2024)

  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Kidney Cancer
  • Liver Cancer
  • Blood Cancer
  • Lung Cancer
  • Others

Europe Molecular Diagnostics Infectious Disease, By Application Outlook (Market Revenue in USD Million, 2013 – 2024)

  • Methicillin-resistant Staphylococcus aureus (MRSA)
  • Clostridium difficile
  • Vancomycin-resistant enterococci
  • Carbapenem-resistant bacteria testing
  • Flu
  • Respiratory syncytial virus (RSV)
  • Candida
  • Tuberculosis and drug-resistant TB
  • Meningitis
  • Gastro-intestinal panel testing
  • Chlamydia
  • Gonorrhea
  • HIV
  • Hepatitis C
  • Hepatitis B
  • Other

Europe Molecular Diagnostics Genetic Testing, By Application Outlook (Market Revenue in USD Million, 2013 – 2024)

  • Newborn screening
  • Predictive and presymptomatic testing
  • Others

Europe Molecular Diagnostics Country Outlook (Market Revenue in USD Million, 2013 – 2024)

  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Belgium
  • Switzerland
  • Netherlands
  • Poland
  • Austria
  • Greece
  • Sweden
  • Turkey
  • Finland

Access press release of this research report by Grand View Research:

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.


Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc


Read our blogs –,